House Bill No. 1154 aims to prohibit commercial insurers from requiring prior authorization for certain generic medications that are not opioids when prescribed by qualified healthcare providers, specifically board-certified physicians or authorized providers. The bill introduces new definitions for terms such as "board-certified physician," "commercial insurer," "generic medication," and "prior authorization." It specifies that prior authorization will not be necessary if the wholesale acquisition cost of the medication is $250 or less per prescription and the prescribing provider's specialty certification aligns with the medical indication for the drug.

The provisions of this bill will apply to any new health insurance policy, contract, or coverage plan issued on or after January 1, 2027. Existing policies will need to conform to the new requirements by their renewal date, but no later than January 1, 2028. The bill reflects a significant shift in the approach to medication access, aiming to streamline the process for patients needing essential generic medications while ensuring that qualified providers can prescribe them without additional administrative hurdles.